Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials
- 1 January 2016
- journal article
- research article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 91 (1), 51-60
- https://doi.org/10.1016/j.mayocp.2015.10.019
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart DiseaseCirculation, 2014
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 DiabetesThe New England Journal of Medicine, 2011
- Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBsAmerican Journal of Cardiovascular Drugs, 2009
- Telmisartan to Prevent Recurrent Stroke and Cardiovascular EventsThe New England Journal of Medicine, 2008
- Telmisartan, ramipril, or both in patients at high risk for vascular eventsThe New England Journal of Medicine, 2008
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)The Lancet, 2003
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statementThe Lancet, 1999
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsArchives of Internal Medicine, 1988
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986